Due to the work of Professor Keith Chappell and his research group, the AIBN has the knowledge and infrastructure to ensure Australia can develop and deliver clinical-grade vaccines whenever, and wherever, they are needed.
The second-generation Molecular Clamp platform technology enables the rapid generation of viral subunit vaccines, which are safe, elicit an optimal response, are rapid to produce, cost-effective and thermal stable. The Chappell Group leverages the Molecular Clamp technology towards two major projects; one funded by the Coalition for Epidemic Preparedness Innovations (CEPI), which focuses on building a rapid response vaccine pipeline to safeguard against future pandemics, and the second comprising contract research for Biotech spinout, Vicebio Pty Ltd, that seeks to develop highly-effective vaccines for respiratory viruses.
Crucial to these projects are the specialist NCRIS-funded production facilities housed at the AIBN, including the National Biologics Facility (NBF), which enables AIBN researchers to identify and translate biomedical research discoveries, bridging the gap between early-stage development, testing and clinical supply, and Protein Expression Facility (PEF) which specialises in recombinant protein production to advance our cutting-edge research.
Read the full story from the Australian Institute for Bioengineering and Nanotechnology here.
Professor Keith Chappell
Comments